<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04308070</url>
  </required_header>
  <id_info>
    <org_study_id>TP0148</org_study_id>
    <nct_id>NCT04308070</nct_id>
  </id_info>
  <brief_title>Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia III</brief_title>
  <acronym>AHAIII</acronym>
  <official_title>Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PROCEPT BioRobotics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PROCEPT BioRobotics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A dual-arm prospective, interventional clinical trial to evaluate the safety and performance
      of obtaining hemostasis with catheters along with the use or absence of a hemostatic agent
      following treatment with the AQUABEAM System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROCEPT BioRobotics has developed the AQUABEAM, a personalized image-guided waterjet
      resection system that utilizes a high-pressure saline stream to resect and remove prostate
      tissue in males suffering from LUTS due to BPH. The primary objective of this study is to
      evaluate the safety and performance of obtaining hemostasis using balloon catheters with and
      without hemostatic agents following prostate resection using AQUABEAM for the treatment of
      LUTS resulting from BPH. Up to 50 participants will be included in the trial at one clinical
      study site. All patients will be followed up for 3 months for safety assessment prior to
      study exit. The trial is a dual-arm prospective, interventional clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 18, 2017</start_date>
  <completion_date type="Actual">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">March 22, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects that do not require a transfusion and do not return to the operating room for hematuria management within 7 days following the index procedure.</measure>
    <time_frame>7 days post-op</time_frame>
    <description>Adequate hemostasis post-Aquablation with the use of a urinary catheter and / or delivery of a hemostatic agent, measured by the number of subjects that, within 7 days following the index procedure, do not require a transfusion and do not return to the operating room for hematuria management.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Catheter without Hemostatic Agent Following Aquablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AQUABEAM System followed by catheter without hemostatic agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Catheter with Hemostatic Agent Following Aquablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AQUABEAM System followed by catheter with hemostatic agent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AQUABEAM System followed by catheter without hemostatic agent</intervention_name>
    <description>The AquaBeam system delivers a high-pressure saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The physician will use balloon catheter to achieve hemostasis post-Aquablation procedure.</description>
    <arm_group_label>Catheter without Hemostatic Agent Following Aquablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AQUABEAM System followed by catheter with hemostatic agent</intervention_name>
    <description>The AquaBeam system delivers a high-pressure saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The physician will use balloon catheter with hemostatic agent to achieve hemostasis post-Aquablation procedure.</description>
    <arm_group_label>Catheter with Hemostatic Agent Following Aquablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  BPH symptoms

        Exclusion Criteria:

          -  Serious concurrent medical conditions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Muljibhai Patel Urological Hospital</name>
      <address>
        <city>Nadiad</city>
        <state>Gujarat</state>
        <zip>387001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 4, 2017</study_first_submitted>
  <study_first_submitted_qc>March 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2020</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Image-guided</keyword>
  <keyword>BPH</keyword>
  <keyword>Aquablation</keyword>
  <keyword>AQUABEAM</keyword>
  <keyword>LUTS</keyword>
  <keyword>Tissue resection</keyword>
  <keyword>Robotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

